Simulations Plus

Simulations Plus Inc is engaged in the software industry. It includes two segments. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.

Earnings

News

Dividends

Small Cap

Markets

Analyst Ratings

Tech

Trading Ideas

ANSS

MANH

Simulations Plus, Inc. (NASDAQ: SLP) has streamlined its business unit and leadership structure to foster growth after recent acquisitions. These updates will be implemented on Aug 30, 2024.

Simulations Plus Restructures Business Unit Post-Acquisitions

Stocks Photo by Jirapong Manustrong on Shutterstock

Pre-Market Outlook

Movers

AMSWA

FFWM

NOAH

RPAY

Simulations Plus Posts Q3 Results, Joins First Foundation And Other Big Stocks Moving Lower In Wednesday&#39;s Pre-Market Session

Market,Sentiment,,Fear,And,Greed,Index,,Emotional,On,Stock,Market

AAPL

MSFT

RDUS

Market sentiment improved as Nasdaq gains record level. S&amp;P 500 and Dow Jones also rose, while some sectors closed negatively. Fear &amp; Greed Index at 48.1.

Nasdaq Closes At Record High Led By Microsoft And Apple: Fear &amp; Greed Index In &#39;Neutral&#39; Zone

Simulations Plus Inc

Smooth Love Potion - United States Dollar

SIMPLEX HLDGS INC by SIMPLEX HLDGS INC.

Press Releases

Simulations Plus and Partners Awarded New FDA Grant to Validate In Vitro-In Vivo Extrapolation Methods for Complex Formulations

Simulations Plus to Participate in the Stephens Annual Investment Conference

Simulations Plus and the University of Connecticut Receive New FDA Grant to Expand Mechanistic Modeling Approaches for Long-Acting Injectables

Simulations Plus to Participate in the BTIG Digital Health Forum

Simulations Plus Announces First Quarter Fiscal Year 2025 Earnings and Conference Call Date

Simulations Plus Reports First Quarter Fiscal 2025 Financial Results

Simulations Plus Supported Development of Every FDA-Approved Drug in 2024

Simulations Plus and Enabling Technologies Consortium Announce Strategic Collaboration to Advance GastroPlus® Enhancements

Simulations Plus to Participate in Upcoming Healthcare Investor Conferences

Simulations Plus to Present at the KeyBanc Capital Markets Virtual Healthcare Investor Forum

Firefly Neuroscience, Inc. - Common Stock

Firefly Neuroscience

American Well Corporation Class A Common Stock

American Well

CareCloud

Certara

Claritev Corporation Class A Common Stock

Claritev

Definitive Healthcare Corp. - Class A Common Stock

Definitive Healthcare

Doximity

DarioHealth

Evolent Health

Forian

GoodRx Holdings, Inc. - Class A Common Stock

GoodRx Holdings

Health Catalyst

HealthStream

icad

LifeMD

OneMedNet

OptimizeRx

Phreesia

Pheton Holdings Ltd - Class A Ordinary Shares

Pheton Holdings

Schrodinger

Sophia Genetics

TruBridge

Teladoc Health

Veeva Systems

Waystar Holding

Keybanc

Stephens & Co.

BTIG

Craig-Hallum

Comments

Simulations Plus

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga